Early-phase ERK activation as a biomarker for metabolic status in Fragile X syndrome

60Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Lack of production of the Fragile X Mental Retardation Protein (FMRP) leads to changes in dendritic morphology and resultant cognitive and behavioral manifestations characteristic of individuals with Fragile X syndrome (FXS). FMRP is an RNA-binding protein that is believed to regulate the translation of a large number (probably over 100) of other proteins, leading to a complex and variable set of symptoms in FXS. In a mouse model of FXS, we previously observed delayed initiation of synaptically localized protein synthesis in response to neurotransmitter stimulation, as compared to wild-type mice. We now likewise have observed delayed early-phase phosphorylation of extracellular-signal regulated kinase (ERK), a nodal point for cell signaling cascades, in both neurons and thymocytes of fmr-1 KO mice. We further report that early-phase kinetics of ERK activation in lymphocytes from human peripheral blood is delayed in a cohort of individuals with FXS, relative to normlal controls, suggesting a potential biomarker to measure metabolic status of disease for individuals with FXS. © 2008 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Weng, N., Weiler, I. J., Sumis, A., Berry-Kravis, E., & Greenough, W. T. (2008). Early-phase ERK activation as a biomarker for metabolic status in Fragile X syndrome. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 147(7), 1253–1257. https://doi.org/10.1002/ajmg.b.30765

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free